Dearling J L J, Pedley R B
Cancer Research UK Targeting & Imaging Group, Department of Oncology, University College London (Hampstead Campus), London, UK.
Clin Oncol (R Coll Radiol). 2007 Aug;19(6):457-69. doi: 10.1016/j.clon.2007.03.016. Epub 2007 May 29.
Radioimmunotherapy (RIT) is a method of selectively delivering radionuclides with toxic emissions to cancer cells, while reducing the dose to normal tissues. Although primary tumours can often be treated successfully with external beam radiotherapy or surgery, metastases often escape detection and treatment, leading to therapy failure, and these can be treated with systemic targeted therapies such as RIT. This review describes more recent developments in the field, including both technological developments from the laboratory and increasingly encouraging findings from clinical studies.
放射免疫疗法（RIT）是一种将具有毒性辐射的放射性核素选择性地输送到癌细胞，同时减少对正常组织剂量的方法。尽管原发性肿瘤通常可以通过外照射放疗或手术成功治疗，但转移瘤常常难以被检测和治疗，从而导致治疗失败，而这些转移瘤可以通过RIT等全身靶向疗法进行治疗。本综述描述了该领域的最新进展，包括实验室的技术发展以及临床研究中越来越令人鼓舞的发现。
